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Biotechnology advances have the potential to dramatically change the practice of medicine. Currently
research is underway to ﬁnd cures for diseases that were before untreatable, and many biotechnology products
are already on the market improving the drugs and devices we use today. However, one important factor
to ensure that the pace of biotechnology goes on unhindered is proper regulation. As the guardian of
public health, the Food and Drug Administration has struggled to meet the demands of the rapidly growing
ﬁeld. In particular, the FDA has recognized three potential breakthrough areas of biotechnology that may
need regulatory reform: cell and gene therapy, pharmacogenetics / pharmacogenomics, and novel drug
delivery. This paper will examine the current state of these three technologies and the regulatory landscape
surrounding them.
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I.
4Introduction
The drugs, techniques, and tools developed through biotechnology have the potential to dramatically change
the health and quality of life of current and future generations. The ﬁeld of biotechnology uses knowledge
from almost every scientiﬁc discipline including chemistry, biology, engineering, computer science, and ma-
terial science to improve current medicine and ﬁnd innovative solutions to almost every medical condition.
In only three decades the amount of biotechnology progress has been remarkable and continues to gener-
ate excitement across many audiences, including academics, pharmaceutical companies, investors, and the
general public.1
As the pace of drugs discovered through traditional pharmaceutical approaches has been slowing,2 many
people are looking to biotechnology to both fuel the pipeline of drugs and make the process of drug develop-
ment safer and more eﬃcient. While the work by researchers and scientists is one essential element to getting
these new technologies to market, another important aspect of introducing innovative medical technology to
the public is a regulatory framework that will ﬁnd the proper balance between speed and safety. The Food
and Drug Administration (FDA) is the agency that has been charged by our government to ensure the safety
and eﬃcacy of all medical products sold to the public3. Any innovative drug or device must be approved by
the FDA before it can be sold to the public. The FDA also imposes regulations on the way a medical product
is developed and tested. After a product is introduced to the public, the FDA has continuing authority to
1See Cynthia Robbins-Roth, From Alchemy to IPO: The Business of Biotechnology, 19 (2000). Genentech, Inc. was the ﬁrst
biotech company to go public in October 1980.
2See Overview of FDA Regulation of Human Medicinal Products Developed with Biotechnology, 718 PLI/Pat 979, 995-97
(2002) [herinafter Overview of FDA Regulation].
3Federal Food Drug and Cosmetic Act, 21 U.S.C. § 362. See also the FDA Mission Statement, “The FDA is responsible for
protecting the public health by assuring the safety, eﬃcacy, and security of human and veterinary drugs, biological products,
medical devices, our nation’s food supply, cosmetics, and products that emit radiation. The FDA is also responsible for
advancing the public health by helping to speed innovations that make medicines and foods more eﬀective, safer, and more
aﬀordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve
their health.”, available at http://www.fda.gov/opacom/morechoices/mission.html.
5ensure post-marketing safety.
While government regulation is necessary to ensure that only products that have a suﬃcient risk to beneﬁt
tradeoﬀ are allowed to reach the public, the regulatory pathway that a product must go through to obtain
FDA approval can often be a long and costly process. The total development time for a new drug is
approximately ten to ﬁfteen years4, and estimates for the total cost of developing a new drug and bringing
it to market is $500 million, which includes the costs for failed candidates5. The FDA requires products to
go through a rigorous testing period conducted in multiple phases. After the candidate has completed the
required clinical tests, an application is then submitted to the FDA for review. The time required to review
the application can take approximately one to two years6.
In recent years, the FDA has responded to criticisms of regulatory delay by embarking on several initiatives
designed to accelerate the drug and device development process7. While these measures have resulted in
signiﬁcant improvements, the FDA faces a much larger challenge with the task of improving regulation
of innovative biotechnology products. In a recent 2002 statement titled Improving Innovation in Medical
Technology: Beyond 2002, the FDA acknowledged that its current framework for regulation of medical
products was insuﬃcient for some new areas of biotechnology.8 In particular, the FDA focused on three
areas of biotechnology with breakthrough potential, but high regulatory uncertainty and confusion: (1) cell
and gene therapy, (2) pharmacogenomics/ pharmacogenetics, and (3) novel drug delivery systems.9
4Overview of FDA Regulation, supra note 2, at 997.
5Id.
6Id. at 1003.
7Most notable is the Prescription Drug User Fee Act of 1992, which enabled the FDA to charge a user fee to applicants.
The user fees allowed the FDA to obtain the resources necessary to accelerate the review process.
8Available at http://www.fda.gov/bbs/topics/NEWS/2003/beyond2002/report.html. See also, FDA, Press Release: FDA
Launches New Initiative to Improve the Development and Availability of Innovative Medical Products, Jan. 31, 2003, available
at http://www.fda.gov/bbs/topics/NEWS/2003/NEW00867.html.
9Id.
6This paper will examine these three areas of biotechnology and the regulatory landscape surrounding those
technologies. Part I will describe the technologies and the science behind them. Current advances and
challenges in the technology will be addressed, along with some of the possible applications. Part II will
give a background on the FDA’s regulation of medical products, and an overview of the FDA regulatory
structure. Part III will focus on FDA regulation applied to the three breakthrough areas of biotechnology.
Other relevant regulatory provisions and social issues will also be discussed. The regulatory challenges will
be presented along with recommendations for improvements.
II.
7The Science and Current State of the Technologies
A.
Cell and Gene Therapy
One of the most promising and exciting areas in biotechnology is not based on a drug or chemical, but
instead focuses on altering our own tissues and cells at the most fundamental level. Cell and gene therapy
uses the power inherent in living matter to treat disease and injury. Far from the traditional trial and error
approach to ﬁnding new medicines, cell and gene therapy uses a strategic approach to curing disease by ﬁrst
understanding the underlying mechanisms of the disease and related physiological functions.
1.
Cell therapy
Cell therapy involves treating diseased tissues by adding to the body speciﬁc cells that have been selected
or engineered to make local or systemic changes. While living cells have been used before to treat patients
through procedures such as blood transfusions, organ transplants, and bone marrow transplants, cell therapy
goes beyond typical transplantations by using various techniques to manipulate the cells, combine the cells
with other drugs or devices, or stimulate cell activity10. Some examples of ex vivo (outside the body) ma-
nipulation include “propagation, expansion, selection, puriﬁcation, or alteration of biological characteristics
10Food and Drug Administration, Guidance for Human Somatic Cell Therapy and Gene Therapy 3 (Mar. 1998). The FDA
deﬁnes somatic cell therapy as “the administration to humans of autologous, allogeneic, or xenogeneic living non-germline cells,
other than transfusable blood products, for therapeutic, diagnostic, or preventive purposes.”
8by pharmacological treatment irradiation, or other methods.”11
Most cell therapies use somatic cells, as opposed to germ line cells, meaning the changes will aﬀect only
the current generation and not the reproductive cells. Somatic cell therapies have several dimensions of
classiﬁcation. One important distinction is the source of the cells. If cells used in the therapy are from
the same patient, then the therapy is called autologous.12 Allogenic treatment uses cells that come from a
human donor other than the patient.13 Finally, xenotransplantation uses cells derived from an animal source
that are altered to be compatible with humans.14 Autologous treatments are advantageous because they
are less likely to induce an immune response, but require advance harvesting of the cells from the patient.
Xenotransplantations oﬀer the best option for large scale source of tissues and organs, yet present the most
challenge in terms of compatibility and immune acceptance15.
Somatic cell therapy can also be classiﬁed according to the function of the cells being implanted, which
can be either structural or functional.16 Structural cell therapy involves treating tissues such as cartilage,
muscle, and skin. Autologous structural cell therapies are often referred to in the industry as manipulated
autologous structural (MAS) therapies.17 Some MAS products have already been approved and are currently
being marketing in the United States. Carticelr  is a product marketed by Genzyme for people with cartilage
degradation in the knee joint.18 A small biopsy of the patient’s own cartilage cells are removed, grown in
culture ex vivo, and then implanted back into the injured knee.19 Apligraf and Dermagraft are examples
of marked skin replacement products that use allogenic cells.20 These skin grafts are used for patients with
11Shane M. Ward, Global Harmonization of Regulatory Requirements for Premarket Approval of Autologous Cell Therapies,
55 Food & Drug L.J. 225, 230 (2000).
12See id. at 226.
13Scott R. Burger, GTP/GMP Cell Engineering for Cell and Gene Therapies, BioProcessing Journal, 292 (Jan/Feb 2003).
14Id.
15See Elizabeth Pennisi, FDA OKs Baboon Marrow Transplants, 269 Science 293 (1995). Discussing critics fears of the
increased dangers of infectious disease originating in primates.
16See Shane M. Ward, supra note 11, at 226.
17See id. at 230.
18See http://www.genzymebiosurgery.com/prod/cartilage/gzbx p pt cartilage.asp.
19Id.
20See product websites at http://www.organogenesis.com/content/proddescrp.htm; http://wound.smith-
nephew.com/US/Product.asp?NodeId=2550.
9severe burns or chronic ulcers. Before these products, the only source fore treating these patients was to
transplant their own skin from a diﬀerent area or to use cadaverous tissue.21
Functional cell therapies encompass the use of all other cells that perform a function other than support.
The most widely known form of functional cell therapy is stem cell therapy. Stem cells are the most prim-
itive, undiﬀerentiated form of a cell.22 The primary function of stem cells is to produce other cells. They
are the only cells in the body that have the ability for long term proliferation.23 While most cells have a
limited life span and then die oﬀ, stem cells have the ability to regenerate themselves as well as other cells.24
Stem cells can turn into functional cells, such as blood, liver, heart and brain cell, through a process called
diﬀerentiation.25
Bone marrow transplantation, which has been performed for 40 years, is one of the earliest forms of func-
tional stem cell therapy.26 Today, roughly 40,000 bone marrow transplants are performed each year27. Bone
marrow is rich with stem cells, especially hematopoetic stem cells which generate blood cells.28 Bone marrow
transplants are often used in conjunction with cancer treatments to replenish stem cells after chemother-
apy.29 Bone marrow transplants are used for other indications such as metabolic disorders or autoimmune
disease.30
In an adult, the primary sources of hematopoetic stem cells is the bone marrow or peripheral blood.31
21Id.
22See National Institutes of Health, Stem Cell Information, available at http://stemcells.nih.gov/infoCenter/stemCellBasics.asp
(updated Sept. 2002).
23See Id.
24See Id.
25See Id.
26See Scott R. Burger, supra note 13, at 1.
27Id.
28See Jennifer Kulynych, Blood as a Biological Drug: Scientiﬁc, Legal, and Policy Issues in the Regulation of Placental, and
Umbilical Cord Stem Cell Transplantation, 32 U. Rich. L. Rev. 407, 407-08 (1998).
29See Id.
30See Scott R. Burger, supra note 28, at 1.
31See National Bone Marrow Program, Sources of Stem Cells, at http://www.marrow.org/MEDICAL/sources of stem cells.html
[herinafeter Sources of Stem Cells]..
10However, getting tissue from the marrow can be an extremely painful and invasive process.32 The bone
marrow donation process consists of a one to two hour surgical procedure where the bone marrow is usually
removed from the hip or back. Donors may have pain for several weeks after the procedure. The other
source of hematopoetic stem cells in an adult is the peripheral blood.33 However, the stems cells are found
in a much lower concentration, and the donor blood must be ﬁltered to get a concentrated sample.34 Also,
stem cells used in peripheral blood transplants are more likely to have adverse aﬀects on the patient, such
as chronic graft versus host disease.35
The other source for stem cells is umbilical cord blood from a newborn. The cord blood is collected at time
of birth and causes no pain to the mother or child.36 The blood is stored on a cord blood bank for future
use. Cord blood has a lower incidence of rejection by the recipient and has a broader compatibility proﬁle.37
Also, scientists are currently working on developing special processes that can select for stem cells and then
expand the number of those cells ex vivo, which could make autologous stem cell therapy a viable treatment
option.
The most controversial source of stem cells is from a human embryo. Harvesting embryo cells requires
combining a donor egg and sperm in vitro, and then the cell to reproduce.38 The cells organize into an inner
circle and outer circle of cells.39 The cells in the inner circle have been found to be an extremely valuable
type of stem cell that can generate many diﬀerent types of tissue.40 However, the major ethical debate
surrounding the use of embryos questions whether it is a violation of human life to use embryos as a source
32See National Bone Marrow Program, Steps of Marrow and PBSC Donation at
http://www.marrow.org/DONOR/steps of donation.html.
33See Sources of Stem Cells, supra note 31.
34See Jennifer Kulynuch, supra note 28, at 411.
35Id. at 413.
36Id.
37Id.
38See Stem Cell Information, supra note 31.
39Id.
40Id.
11of medical treatment.41
An example of cell therapy using diﬀerentiated cells is transplantation of pancreatic islet cells for Type I
diabetes, which is currently in clinical trials.42 The current treatment options for Type I diabetics is either
carefully monitoring of blood sugar levels with frequent insulin injections or a whole organ transplant of
the pancreas and kidney.43 Cell therapies using pancreatic islet cells, which are speciﬁcally responsible for
producing insulin, oﬀer many advantages over the traditional treatments. If successfully implanted, the cells
would provide a long term source of insulin, instead of regular insulin injections.44 Replacing only the cells
instead of the entire organ faces less of a donor shortage problem because it requires only a sample of tissue
rather than a whole organ donation, and the procedure for implanting the cells is less invasive and dangerous
than whole organ replacement.45
Cell therapy is sometimes referred to in the broader context of a related ﬁeld called tissue engineering.
Tissue engineering is a term that encompasses cell therapy along with other non-cell based techniques such
as bioinformatics and biomaterials that are synthetic and biocompatible. The term is a recent concept
that was born in 1987.46 The National Science Foundation’s oﬃcial deﬁnition of tissue engineering is the
application of principles and methods of engineering and life sciences to obtain a fundamental understanding
of structure-function relationships in novel and pathological mammalian tissues and the development of
biological substitutes to restore, maintain, or improve [tissue] function.47 In 2002 over $600 million dollars
41The President’s Council on Bioethics, Monitoring Stem Cell Research (Jan. 2004) available at
http://www.bioethics.gov/reports/stemcell/index.html.
42FDA, Pancreatic Islet Transplantation to Treat Type I Diabetes (Sept. 10, 2003) available at
http://www.fda.gov/cber/genetherapy/pancislet.htm.
43Id.
44Id.
45Id.
46Larry V. McIntire, Introduction, WTEC Panel Report on Tissue Engineering Research, Chapter 1, 1 (Jan. 2002).
47Other related terms that have signiﬁcant overlap with tissue engineering are regenerative medicine and reparative biol-
ogy. See id. (citing the deﬁnition introduced by Skalak and Fox at a 1998 National Science Foundation workshop on tissue
12a year was spent on tissue engineering technologies by over 70 start-up biotechnology companies.48
One of the key applications of tissue engineering is organ replacement and repair. Currently when an organ is
diseased or no longer functioning properly, the organ is repaired or replaced with either a completely synthetic
device or transplanted with an organ from a donor. These traditional methods of organ replacement have
signiﬁcant costs and limitations. Synthetic devices are usually eﬀective at prolonging the life of a patient,
yet are still inferior to a naturally functioning organ. When a synthetic device is implanted permanently,
the body eventually responds with an inﬂammatory reaction that is called a foreign body response.49 This
inﬂammation results in an undesirable layer of scar tissue that forms around the implant50. Through tissue
engineering researchers are developing new biomaterials that would degrade over time and be assimilated
and reabsorbed by the body, thus avoiding an inﬂammatory response.
Transplants from a human donor, while not synthetic, may still be rejected even though it is carefully
matched with the patient’s blood type and other biological factors51. The use of organ transplants as a
reliable treatment is also severely limited by the shortage of organ donors. Currently thousands of people
are on waiting lists for donor organs, many of whom will pass away before an organ becomes available.52
Also, due to the strict tissue matching requirement this means that some minority groups may have a dis-
proportionately long waiting period since there are few matching donors available53.
engineering).
48See id. at 2.
49Linda G. Griﬃth, WTEC Panel Report on Tissue Engineering Research, Chapter 2: Biomaterials, 7 (Jan. 2002).
50Id.
51For example, in kidney transplants a test to match human leukocyte antigen is used to improve acceptance rates. See David
W. Gjertson et al., National Allocation of Cadaveric Kidneys by HLA Matching: Projected Eﬀect on Outcome and Costs, 324
New Eng. J. Med. 1032, 1034-35 (1991).
52See Cynthia Robbins-Roth, supra note 1, at 93. A 1993 study by researchers at MIT showed that each year 4,000 people
on these waiting lists die and 100,000 die before even making it onto a waiting list.
53See, e.g., Steve Takemoto et al., Equitable Allocation of HLA-Compatible Kidneys for Local Pools and for Minorities, 331
New Eng. J. Med. 760, 762-64 (1994); Ian Ayres et al., Unequal Racial Access to Kidney Transplantation, 46 Vand. L. Rev.
805, 815-36, 849-53 (1993).
13Tissue engineering could address these limitations by actually repairing or creating an organ that is equiv-
alent to the patient’s own original tissue. One way of achieving this is to use the patient’s own tissue. 54
For example, a small sample of the patient’s cells could be removed and then grown ex vivo and replanted
inside the body.55 Other technologies focus on creating structural grafts and implants that encourage the
patient’s organ to regenerate and repair itself inside the body.56
2.
Gene therapy
Gene therapy goes one level further than cell therapy by attacking the disease at the nerve center of the
individual cell. The entire blueprint for our physical body is contained in the nucleus of each cell in molecules
called deoxyribonucleic acid (DNA).57 DNA is made up of genes, which control the production of proteins
in our body.58 Proteins are important because they are one of the structural foundations of the body and
special proteins called enzymes control metabolic functions responsible for proper health.59
In 1972 scientists ﬁgured out how to take the DNA out of one cell and place it in another cell.60 With
this technique, genes from one organism could be cut and spliced into the DNA of another organism. This
technique became to be known as recombinant DNA (rDNA).61 The rDNA technology was ﬁrst used to
54See Jennifer Kulynych, supra note 30, at 408.
55See Larry V. McIntire, supra note 46.
56See Id.
57See FDA, Human Gene Therapy and The Role of the Food and Drug Administration, available at
http://www.fda.gov/cber/infosheets/genezn.htm.
58Id.
59Id.
60Joseph M. Rainsbury, Biotechnology and the RAC – FDA/NIH Regulation of Human Gene Therapy, 55 Food & Drug L.J.
575, 576 (2000)
61Id.
14produce large quantities of a speciﬁc protein by implanting the gene for that protein in a bacterial plasmid.62
This technology became the basis for a new class of therapeutic products called genetically engineered
proteins.63 Insulin was the ﬁrst rDNA product developed with rDNA and approved by the FDA for marketing
in 1982.64 Now many other genetically engineered proteins are available to the public including erythropoietin
and growth hormone.65
Gene therapy is the application of rDNA to human patients. Adding genes to human cells could be used to
correct genetic mutations by introducing a functional gene into the cell to replace or correct a defective gene.
After the desired gene is created through rDNA, the gene must be introduced into the patient’s cell using
a carrier molecule called a vector. Currently, the most common vector is a virus that has been stripped of
its disease causing properties and instead holds the therapeutic gene66. Most commonly these viruses are
adenoviruses or retroviruses67. Although viruses are capable of easily penetrating the cell, they may cause
other complications such as an adverse immune response or the virus could disturb unintended functions
in the cell and cause a new disease. Scientists are experimenting with other delivery techniques such as
direct injection of DNA, lipid coated DNA, or linking DNA to molecules that would bind with speciﬁc cell
receptors.68 The process of gene transfer can either be conducted ex vivo, in situ (delivered locally into the
body), or in vivo (delivered systemically).69
Diseases that were thought incurable now have hope for treatment and cure. The location and sequence
for the genes responsible for cystic ﬁbrosis, sickle cell disease, Tay-Sachs disease, fragile X syndrome and
62Linda R. Judge, Biotechnology: Highlight in the Science and Law Shaping the Industry, 20 Santa Clara Computer & High
Tech. L.J. 79, 81 (2003).
63Id.
64Id.
65Id.
66Approximately 25-30% of the vectors used in gene therapy are adenoviruses. Judith A. Cregan, Biotechnology and the Law:
Light, Fast, and Flexible: A New Approach to Regulation of Human Gene Therapy, 32 McGeorge L. Rev. 261, note 26 (2000).
67Id.
68Available at http://www.ornl.gov/sci/techresources/Human Genome/medicine/genetherapy.shtml#whatis.
69Judith A. Cregan, supra note 66, at 265-66.
15myotonic dystrophy have already been discovered.70 Besides diseases causes by a single gene mutations, the
primary focus of gene therapy research has been cancer. Another promising application of gene therapy is
in diseases associated with the brain and psychological function. Genes are ideal therapies because they are
small enough to cross the blood-brain barrier. Gene therapy is currently being investigaged as a cure for
Parkinson’s disease71.
Although much excitement has surrounded the possibilities of gene therapy, currently no gene therapies
have been approved as a marketable therapy. Gene therapy is still an experimental science, with only 1%
of current human trials in Phase III and the rest in early stage testing72. The ﬁrst gene transfer clinical
trial began in 1990 on a 4-year-old girl with severe combined immunodeﬁciency disease (SCID). However,
although the child responded to the treatment, the therapy did not generate enough of a response for it to be
therapeutic. The ﬁeld hit its biggest and most public setback in 1999 when 18-year old Jesse Gelsinger died
in a gene therapy clinical trial at the University of Pennsylvania, one of the leading gene transfer research
centers.73 He died of massive organ failure caused by an immune reaction to the adenovirus vector.74 His
death created alarm in the public, and the ﬁeld was faced with intense scrutiny about the safety of the
science.75 The FDA responded by halting all gene transfer trials at the university and placed a clinical hold
on all other researchers using the same type of virus.76 At the NIH a working group was formed to review
the regulatory framework and look into whether the NIH role in regulation needed to be changed.77
70Linda R. Judge, Biotechnology: Highlight in the Science and Law Shaping the Industry, 20 Santa Clara Computer & High
Tech. L.J. 79, 81, 83 (2003).
71See Undercover Genes Slip Into the Brain at www.newscientist.com (March 20, 2003).
72Nancy M. P. King, RAC Oversight of Gene Transfer Research: A Model Worth Extending?, 30 J.L. Med. & Ethics 381,
382 (2002).
73Judith A. Cregan, supra note 66, at 267-68 (2000).
74Id.
75Id.
76Id.
77Advisory Committee to the Director Working Group on NIH Oversight of Clinical Gene Transfer Research, Enhancing the
Protection of Human Subjects in Gene Transfer Research at the National Institutes of Health, July 12, 2000. From February to
May, 2000, the Working Group, which was comprised of scientists, bioethicists, and representatives of the general public, met
with various representatives from the OBA, NIH, FDA, Oﬃce for Human Research Protection, and RAC.
16However, gene therapy had it’s ﬁrst successful treatment in humans in 2002 in a trial conducted in France.78
The trial involved gene therapy for SCID. Fifteen children were successfully treated for the disease.79 How-
ever, one boy who had been successfully treated developed a leukemia-like condition. The vector that had
introduced the therapeutic gene was thought to have disturbed another part of the cell that was responsible
for cancer suppression.80 The FDA placed a temporary halt on all gene therapy in January 2003 as a result81.
B.
Pharmacogenomics / Pharmacogenetics
Unlike most consumer products, drug manufacturers need not show absolute safety and eﬃcacy of the prod-
uct in order to gain approval. As long as the risks do not outweigh the beneﬁts, the drug can be approved
with ultimate determinations of safety and eﬃcacy for a speciﬁc patient left to the physician. In fact, some
drugs have been approved that have only shown eﬀectiveness in less than half of the subjects in the clinical
trials and many drugs are approved that have caused severe side eﬀects in some subjects.82 Some estimates
say that the current costs from adverse reactions to drugs could be as high as $100 billion annually and more
than 100,000 people die each year from an adverse reaction. 83 As many as 2.2 million other people suﬀer
78New Scientist, ’Miracle’ gene therapy trial halted, Oct. 2, 2003 available at
http://www.newscientist.com/news/news.jsp?id=ns99992878.
79Id.
80Oﬃce of Biological and Environmental Research, Human Genome Project Information, available at
http://www.ornl.gov/sci/techresources/Human Genome/medicine/genetherapy.shtml#whatis.
81Id.
82Lars Noah, The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients’ Genetic Proﬁles, 43 Jurimetrics
J. 1, 4 (2002). One study cites that almost one out of ﬁve approved new drugs cause serious side eﬀects that were not even
discovered until after the drug has been used widely in the market. See Maryann Napoli, Many Prescription Drugs Have
Unexpected Harmful Eﬀects, 5/1/02 HealthFacts, available at 2002 WL 10889054.
83Michael J. Malinowski, Law, Policy, and Market Implications of Genetic Proﬁling in Drug Development, 2002 Hous. J.
Health L. & Pol’y 31, 39 (2002) [herinafter Genetic Proﬁling].
17from other serious side eﬀects, while many other people simply have no reaction at all to a drug.84 Doctors
and patients have had to live with the fact that diﬀerent people will have very diﬀerent reactions to the same
drug. The variability in drug response has left physicians with a lot of guess work and experimenting with
oﬀ-label uses.
Pharmacogenetics and pharmacogenomics are both terms that have been used to describe the science of us-
ing a person’s genetic makeup to facilitate the development and tailoring drugs to the individual to increase
the predictability of response and to reduce the possibility of adverse aﬀects. While pharmacogenetics and
pharmacogenomics have subtle diﬀerences in literal meaning85, both terms tend to be used interchangeably
to refer to the same science. The following discussion will use the term pharmacogenomics, with the intention
to encompass both pharmacogenetics and pharmacogenomics to refer to the broad science of discovering the
relation of between genes and drugs and the susceptibility to disease.
Pharmacogenomics combines both pharmacology and genetics to use our knowledge about genes to reduce
the variability in response to drugs and discover new drug targets. It has long been known that factors such
as race and gender can aﬀect a person’s susceptibility to disease and response to treatment86. Pharmacoge-
nomics can use the power of modern genetic tests to gain similar information for genetic variances that may
not by physically apparent.
Historically, the possibility of gene therapy began more than ﬁfty years ago with the discovery of the double
helix structure of DNA by Watson and Crick87. DNA is the structure in the cell that carries all of our genes.88
Genes control the production of proteins, which is responsible for all life functions within the body.89 The
84Id.
85‘Genetics’ means “the study of inheritance of speciﬁc traits”. ‘Genomics’ means “the study of genes and their function.”
For a detailed explanation of the use of the two terms see Barbara Ann Binzak, How Pharmacogenomics Will Impact the
Federal Regulation of Clinical Trials and the New Drug Approval Process 58 Food & Drug L.J. 103, n. 10 (2003).
86See e.g., Dee Marlo E. Chico, Pharmacogenomics: A Brave New World in Designer Drugs, 5 Scholar 111, 117-18 (2002);
Ron Winslow, Pharmacia Drug Holds Promise for Blacks with Hypertension, WALL ST. J., June 11, 2002, at D4.
87Dee Marlo E. Chico, supra note 86, at 114.
88Id.
89Id.
18building blocks of DNA are four diﬀerent nucleotide bases: adenine (A), cytosine (C), guanine (G), and
thymine (T). The bases are linked up in long chains, and the order of the bases is what determines the iden-
tity and function of a gene. In 1990 the Human Genome Project began the ambitious task of determining
the nucleotide sequence of all the genes in a human.90 With the human genome comprised of approximately
30,000 genes and three billion nucleotides, this was a huge endeavor that took over a decade to complete
with the collaboration of many parties in both the public and private sector.91 The team announced on June
26, 2000 that they had completed a rough draft of the entire human genome sequence.92
Knowing the sequence of DNA is like ﬁnding the blueprint to the human body. The source of all individual
traits and diseases are found in this sequence. The vast majority of the human genome is the same for
everyone, with only 0.1% of the genome varying from person to person93. This 0.1% of the genome accounts
for all of our individual diﬀerences. When a gene sequence deviates from the norm, this is referred to as
a mutation.94 Some mutations can be harmless and while others will be the cause of disease. If a genetic
mutation is found in more than one percent of the population this is called a “polymorphism”95. A polymor-
phism that results from a diﬀerence in just one nucleotide pair is called a single nucleotide polymorphism
(SNP).96
Particular attention has been given to SNPs linked to the metabolism, absorption, and excretion of drugs.
A special enzyme in the liver known as cytochrome P450 has been discovered to have a prominent role in the
oxidation of drugs.97 Many researchers believe that studying the SNPs related to these enzymes will allow
physicians to improve the selection of treatment and dosing on an individual level. For example, researchers
90Id.
91Michael J. Malinowski, Separating Predictive Genetic Testing from Snake Oil: Regulation, Liabilities, and Lost Opportu-
nities, 41 Jurimetrics 23 (2000) [hereinafter Snake Oil].
92Fracis S. Collins et al, A Vision for the Future of Genomics Research, 422 Nature, April 24, 2003.
93Snake Oil, supra note 91.
94Id.
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97Lars Noah, supra note 82, at 7.
19have discovered an SNP that occurs in 5% of the population results in a malfunction in the enzyme that
metabolizes codeine98. Thus, people with that SNP will not get the same pain relief from regular doses of
the drug. If doctors can test for this SNP, they will know to give these individuals an alternate pain relief
medication. On a larger scale, an SNP consortium was founded in 1999 to discover all the SNPs in the entire
human genome.99
Already scientists have discovered the location and sequence for many genes that cause hereditary diseases
that result from a single gene mutation such as cystic ﬁbrosis, Huntington’s disease, and sickle cell ane-
mia.100 Even diseases that are caused by more complicated mechanisms can be detected with genetic tests.
Tests are currently available that may tell a person if they have an increased chance of getting some types
of cancers. 101 Although these tests show only an increased susceptibility to a certain disease, the genetic
test would alert the individual and physician to take early precautions.102 However, many scientists warn
against treating genetic tests as a deﬁnitive or sole factor in making health decisions. The presence of genes
in most cases is only one of many factors that can contribute to the individual’s predisposition to a disease
or reaction to a drug.103
The next stage of research is already under way to use pharmacogenomic data not only as a tool for using
existing drugs, but also to discover new drugs targeted speciﬁcally at a speciﬁc gene type104. Current
conventional drugs target about 500 out of the 30,000 protein coding genes105. Understanding the function
of genes and the protein path it regulates can give scientists a targeted goal for developing new drugs.
98Id. See also, Soren H. Sindrup & Kim Brosen, The Pharmacogenetics of Codeine Hypoalgesia, 5 PHARMACOGENETICS
335, 343 (1995).
99Available at http://www.ncbi.nlm.nih.gov/SNP/.
100Id.
101Tests for the BRCA can show a increased risk for breast cancer. See Snake Oil, supra note 91.
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104Andrew Pollack, Drug Developed from Gene Study Tested on People, N.Y. TIMES, Feb. 26, 2001, at C14.
105Francis S. Collins et al, supra note 92.
20Some successful treatments have already been developed that target a speciﬁc genotype. For example,
Genentech’s Herceptin is a marketed breast cancer treatment developed for women only with the Her-2-
neu gene106, and Millenium Pharmaceuticals is developing a drug for leukemia targeting individuals with a
speciﬁc genotype.107 Also, in 2002 the FDA approved of a home genetic testing kit by Visible Genetics, now
acquired by Bayer, that predicts which HIV treatments may be most eﬀective.108 FDA also has approved
the use of genetic test information on drug labels. For example, Eli Lilly’s drug Strattera for attention deﬁcit
disorder comes with labeling that states that a genetic test is available to determine whether an individual
has a genetic proﬁle that would result in slower processing of the drug, which would mean that person would
require a lower dosage of the drug.109
The future progress for pharmacogenomics may be even more rapid as new technologies being developed
related enabling technologies is allowing for rapid sequencing of genomes to the point that gene sequencing
could be accomplished in days rather than years110. Enabling technologies such as biochips and microarrays
are allowing scientists to sequence genes in bulk.111 Advances in bioinformatics are making it possible to
process the enormous amounts of data generated from gene sequences to make functional linkages and turn
data into useful information about physiological function.
It was proposed that some pharmaceutical manufacturers might be wary of using pharmacogenomics ap-
proaches for fear of fragmenting patient populations thus reducing the possibility of “blockbuster” drug
revenues.112 However, many companies are embracing the new technology as a way to diﬀerentiate their
106Genetic Proﬁling, supra note 83, at 42.
107Id.
108Visible Genetics, Inc. News from The BioSpace Beat, FDA Clears New Software For Bayer’s HIV Genotyping Test, Nov.
2002. available at http://www.biospace.com/b2/news company.cfm?CompanyID=2857.
109Anna Wilde Mathews, FDA Will Issue Rules on New Era of ‘Personalized Medicine’, Wall St. J. B1 (Nov. 3, 2003).
110One company has already developed the genetic map for the entire population of Iceland. See http:\\www.decode.com.
111Charles Vorndran, Ph.D. & Robert L. Florence, Bioinformatics: Patenting the Bridge between Information Technology and
the Life Sciences, 42 IDEA 93 (2002).
112See, e.g., Geeta Anand, Big Drug Makers Try to Postpone Custom Regimens, WALL ST. J., June 18, 2001, at B1.
21product as superior, which could command a premium price.113 Pharmaceutical companies could also get
additional revenues from the sale of diagnostic genetic test kits. Furthermore, pharmacogenomics would
allow many companies to “rescue” many failed drug candidates that showed promise in clinical trials, but
were rejected do to adverse eﬀects in some of the patients.
C.
Novel Drug Delivery
Even if a pharmaceutical company can invent a compound that is eﬀective at treating a certain disease, the
next challenge is getting the drug to the area of the body that needs treatment without disturbing other
functions which could produce harms that outweigh the beneﬁts of the treatment. Delivering drugs locally,
meaning directly to the tissue, instead of systemically opens up the possibility of using compounds that were
previously found eﬀective, but considered too dangerous to deliver systemically.
Research in novel drug delivery techniques seeks to maximize the eﬀectiveness, safety, and ease of using
existing drugs. When most people think about how drugs are administered to the human body, only a
limited number of options probably come to mind. For example, drugs in the form of pill must ﬁrst get
metabolized and be absorbed systemically. Insulin must be administered by injection directly into the
bloodstream because the digestive process would destroy the protein.
However, new advances in drug delivery technology are making extreme advances in our delivery options.
Advances in drug delivery could allow for new modes where drugs could be inhaled, transmitted through
113Genetic Proﬁling, supra note 83, at 31.
22the skin, or even implanted inside the body. Furthermore, the precision with which the drug dosage is
administered could be vastly improved. Some day it may be possible to have implanted devices that would
periodically dispense medicines like insulin or morphine.114
Recognizing the importance of drug delivery techniques, the National Institutes of Health recently published
a Request for Applications (RFA) to encourage research in this area.115 The NIH described several areas
where drug delivery research would provide vast improvements in public health. Drug delivery technology
to improve the accuracy and convenience of drug dosing and administration. Some of the problems and side
eﬀects of many drugs can be eliminated by having a more precise dosage of drug. Drug delivery can also
make delivery of drugs more convenient and less painful to administer. New techniques that sustain the level
of drug for a longer period of time can result in reduced.
Drug delivery also addresses many problems of how to get the drug into the patient’s bloodstream in the
least invasive way. Some drugs, for example insulin, cannot be taken orally because the digestive system
would destroy the activity of the drug. Therefore, many people must take their insulin treatments through
painful injections that must be administered several times a day. Novel techniques in drug delivery are now
looking at alternative methods of insulin delivery – either through transdermal or ....
Drug delivery research is also being done to improve the eﬀectiveness of devices. This has been especially
eﬀective for cardiovascular devices. Companies like Boston Scientiﬁc, Corp. and Johnson & Johnson have
developed drug coated stents to improve the success rate after a cardiac surgery.116 In a typical procedure,
a angioplasty balloon is inserted into the artery to clear the blockage, and then a metal stent is permanently
114John Miller, 2002-2003 Beyond Biotechnology: FDA Regulation of Nanomedicine, 4 Colum. Sci. & Tech. L. Rev. 1, 3
(2003).
115National Institute of Biomedical Imaging and Bioengineering, Development of Novel Drug and Gene Delivery Systems and
Devices, RFA: EB-03-011 (December 30, 2002).
116See Marilyn Alva, The Battle over Stents is Picking up Steam, Investor’s Business Daily, Sept. 11, 2003 at A07.
23implanted into the artery to support the artery and prevent it from collapsing.117 However, after a stent is
placed inside the artery, the presence of the foreign object often causes the blood around the area to clot and
block the artery shortly after the surgery.118 Coating the stent with a drug that would prevent the clotting
a proliferation of scar tissue has dramatically improved the success of these surgeries.
Drug delivery is also a concern in gene therapy. Researchers are currently working on the challenge of getting
the desired gene into the cell. The current technique of using viral vectors is less than optimal as it creates
undesirable immune responses and can have unintended eﬀects on the cell. New techniques in delivering
genes using nanotechnology or synthetic systems could eliminate these adverse eﬀects.119 Scientists have
even developed a way to administer a gene to the brain, which is particularly diﬃcult be because of the
“blood-brain barrier”.
III.
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24Food and Drug Administration Regulation
A.
History and Evolution of the FDA
Oﬃcial government regulation of food and drugs in the United States has existed for roughly a century. The
enactment of the Pure Food and Drug Act in 1906 marked the ﬁrst statute dedicated to the safety of food
and drugs.120 The Food Drug and Cosmetics Act was passed in 1938 and marked a dramatic increase in the
regulatory power of the FDA.121 FDA gained authority to require premarket approval of drugs to ensure its
safety before being sold to the public.122 With the 1962 Kefauver-Harris Amendments, the FDA increased
its scope of regulatory power by adding to its premarket requirements that the drug not only be safe, but
also eﬀective for its intended use.123
The FDA did not gain responsibility over biologics until 1972, even though the Biologics Act was ﬁrst pro-
mulgated in 1902.124 The Hygienic Laboratory, which later became the National Institutes of Health (NIH),
was responsible for enforcing the Biologics Act.125 The main purpose of the Biologics Act was to prevent
contamination and the spread of disease.126 The main biologic products at that time were crude human
and animal extracts, with little to no technology for puriﬁcation or testing, the main focus of regulation was
on the manufacturing process.127 In 1944 the Public Health Service Act reenacted the Biologics Act and
120See FDA History, available at http://www.fda.gov/oc/history/default.htm.
121Id.
122Id.
123Id.
124See Gary E. Gamerman, Regulation of Biologics Manufacturing: Questioning the Premise, 49 Food & Drug L.J. 213, 215-19
(1994)
125Id.
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25added that biologics regulation had to be consistent with the FDCA, thereby imposing product licensing
requirements for the ﬁrst time.128 A move toward more stringent biologics regulations was prompted by a
tragedy in 1955 when some children were infected by polio after receiving a vaccination.129 This prompted
the formation of the Division of Biological Standards in the NIH and a new focus on tightening regulations.
Congress eventually transferred DBS to the FDA in 1972, which then became the Center for Biologic Eval-
uation and Research (CBER).130
FDA regulation of medical devices has also been fairly recent. Medical devices did not come into the scope
of FDA’s responsibilities until the FDCA of 1938.131 However, the FDA was only given authority to reg-
ulate the product after it had entered the market.132 The ﬁrst statute providing for premarket approvals
of medical devices was enacted in 1976 with the Medical Device Amendments.133 With this amendment,
the FDA’s distinct and separate regulation of medical devices was promulgated. Unlike pharmaceuticals,
medical devices can include a broader range of products posing diﬀerent risk proﬁles.134 Medical devices
can include tongue depressors and bedpans, on one hand, all the way to pacemakers and brain scanning
machines.135 Therefore, the center at the FDA responsible for devices, the Center for Devices and Radiolog-
ical Health (CDRH) established a risk-based approach to medical devices, with three classes of devices with
varying levels of regulatory controls. The Safe Medical Devices Act of 1990 (SDMA) was the next statutory
addition to medical device regulation, largely responding to complaints about delays in device classiﬁcation
inadequate adverse event reporting.
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26B.
Current State of the FDA
In 1997 the FDA enacted the Food and Drug Administration Modernization Act, the most wide sweeping
amendments to the FDCA since the 1962 Amendments.
In recent decades, the biggest criticism of the FDA was the long approval times after an application was
submitted. In the 1980’s review times averaged around two years.136 The pressure to accelerate drug
approvals came from a variety of sources including industry groups, patient rights advocates, and Congress.
In 1992, the FDA responded with the Prescription Drug User Fee Act (PDUFA). PDUFA introduced a user
fee system where a drug sponsor had to submit a fee with each new drug application. With the fees generated
from PDUFA, the FDA could hire additional resources to dedicate to application reviews, but in return the
FDA had to commit to certain performance standards. The PDUFA was drafted to automatically expire in
ﬁve years, so the FDA had incentive to meet the performance standards that would signal Congress to renew
the user fee provisions. The user fees were a success with a 50% improvement in approval times.137 Thus,
the user fee program was renewed in 1997 (PDUFA II) and again in 2002 (PDUFA III). While at ﬁrst, the
user fee program applied only to drugs and biologics, the Food and Drug Modernization Act of 2002 ﬁnally
extended the user fee programs to medical devices as well. Currently all standard applications to the FDA
fall under a user fee requirement, unless the application is eligible for one of the statutory exceptions.
While user fees have successfully reduced review times, some critics warned against possible conﬂicts of
interest and industry capture at the FDA. In 2002 user fees brought in $137.7 million to the FDA budget,
136Mary K. Olson, How Haver User Fees Aﬀected the FDA?, Regulation April 1, 2002.
137Id.
27which is almost half of FDA’s total spending on review activities.138 Another fear is that with the increasing
reliance on industry funds, Congress may decrease FDA’s allocation of funding even further, thus jeopardizing
FDA’s other funding.139
Recent product withdrawals and an increase in adverse events is also pulling the FDA toward to opposite
direction of increased caution. High proﬁle recalls of drugs such as Redux (phen-fen), Baycol, Propulsid,
and Rezulin have raised questions of whether FDA is letting some products through the gate that should
never have been approved.140 Serious side eﬀects have also increased a dramatic 89% from 1993 to 2000.141
While the FDA would like to be able to use some of the user fees towards post-marketing surveillance, the
industry has been opposed.142
Even with the user fee programs and increase in adverse events, the FDA is still being pressured to improve
its review times. In recent years, the FDA has been under increased scrutiny as the average review time has
increased and the number of new application is at a low point since the user fee program has been enacted.143
In 2002 the FDA reaﬃrmed its goal toward speed and eﬃciency summarized in “Improving Innovation in
Medical Technology: Beyond 2002”.144 FDA Commissioner Mark B. McClellan was in part responding to
the decreased number of drug approvals in the recent years. In order to facilitate development, the Commis-
sioner pointed to several strategies to reduce review times. The ﬁrst initiative focuses on reducing multiple
review cycles by improving early stage communications with the sponsor.145 As part of this program the
FDA will give advice to product developers early in the development process to ensure the studies and trials
are designed in a way that avoids some of the major mistakes that can delay approval. Second, the FDA
138See Overview of FDA Regulation, supra note 2, at 987.
139See Mary K. Olson, supra note 136.
140See Overview of FDA Regulation, supra note 2, at 1001.
141Overview of FDA Regulation, supra note 2, at 999.
142Id. at 1002.
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28proposed to conduct a root cause analysis to see what the primary sources of delay in the cycle were.146 The
FDA also plans to publish a Good Review Management Principles (GRMPs) as a guidance document for
reviewers.147
C.
The Regulatory Lifecycle
The FDA is involved from the very formative stages of the development process. The development process
is divided into several stages: pre-clinical, Phase I, Phase II, and Phase III studies.148 Pre-clinical research
involves all the laboratory and animal studies done prior to tests on human subjects.149 Before the FDA
allows testing on humans to begin, the sponsor must show that the drug or device is not toxic in at least
two diﬀerent animal models.150 During these animal studies, a pharmacologic proﬁle of the drug or device is
developed. Parameters such as toxicity, absorption, and mechanism of metabolism are measured.151 After
the preclinical research is ﬁnished, a sponsor can then ﬁle either an investigational new drug (IND) for new
drugs and biologics or investigational device exemption (IDE ) for devices to the FDA. A sponsor must get
FDA approval before starting any human studies, since it is illegal under the FDCA to use any medical
products in humans before they are approved for marketing.
Throughout clinical trials a local institutional review board (IRB) must oversee and approve of all protocols
146Id.
147Id.
148See generally FDA, Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products
(Mar. 2004).
149Id.
150These studies typically range from a few weeks to three months. Barbara Ann Binzak, How Pharmacogenomics Will Impact
the Federal Regulation of Clinical Trials and the New Drug Approval Process 58 Food & Drug L.J. 103, 114 (2003).
151See supra note 142.
29for human research.152 Human clinical studies conducted with government funding are also subject to federal
law protecting human research subjects referred to as the “Common Rule”153. Human research protection
focuses mainly on issues of safety, informed consent, patient selection, and patient conﬁdentiality154.
Clinical tests in human is conducted in three phases. Phase I involves the smallest number of subjects (20
to 80) and tests for basic safety, typically in healthy subjects.155 Phase II then expands the study and starts
to gather additional safety data as well as evaluate eﬃcacy.156 Phase III is a large scale study, ranging from
several hundred to several thousand subjects, to conﬁrm safety and to validate eﬃcacy and proper dosing
levels.157 After the completion of the Phase III study, the sponsor submits its ﬁnal application to the FDA
for review in hopes of gaining marketing approval.
The sponsor usually meets several times with the FDA in the development process. The most common
meeting times are after Phase II, to get FDA’s input on how to design the Phase III trials, and right before
submitting the ﬁnal application to clarify what data and information the FDA will need to have158.
Within 60 days of submission the FDA must decide to accept the application for review or deny a review
all together because missing information or tests. If accepted, the FDA then reviews the application thor-
oughly and issues an “action letter” which notiﬁes the sponsor of their decision which is either “approved”,
“approvable”, or “not approvable”. An “approved” drug or device can then be marketed to the public. An
“approvable” product will likely be approved, but requires additional data or changes to the labeling. A
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30“not approvable” drug has been determined to have serious deﬁciencies, and will probably not be approved
in the future. After marketing approval, FDA may also require Phase IV studies to measure post-marketing
safety.159 FDA also imposes manufacturing and labeling guidelines that must be met before approval is
granted.
D.
Structure of Regulation
The FDA regulates all products under three basic categories: drug, device, or biologic. The FDA is or-
ganizationally structured around these three categories with the Center for Drug Evaluation and Research
(CDER), the Center for Devices and Radiological Health (CDRH), and the Center for Biologics Evaluation
and Research (CBER). Each center is a discrete unit with its own regulatory processes and requirements for
approval.
1.
Regulation of Drugs.
Section 201(g)(1) of the FDCA deﬁnes a “drug” as anything “intended for use in the diagnosis, cure, mitiga-
tion, treatment, or prevention of disease in man or other animals” or “intended to aﬀect the structure or any
159Id.
31function of the body of man or other animals”.160 The CDER has several categories of NDA submissions
according to its type and indication.161 If the drug is a novel compound that has never before been approved
for marketing, it is called a new molecular entity (NME). Otherwise, the application could be for a new
formulation of an already approved drug, a combination of two or more approved drugs, or a new indication
for an already approved drug.162
If the NDA is an application for a product that is a signiﬁcant advance over existing treatments, the FDA
may give the application a priority status. Otherwise, the NDA goes through the standard review process.
The FDA has committed to review times of 10 months for standard NDA’s and 6 months for priority NDA’s
under PDUFA III.163
2.
Regulation of Biologics
Section 351(a) of the Public Health Service Act (PHSA) deﬁnes “biologic” as a “virus, therapeutic serum,
toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, or
arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable
to the prevention, treatment, or cure of a disease or condition of human beings”164. “Analogous product”
includes “attenuated viruses, whole blood or plasma, blood and plasma derivatives, product acting through
16021 U.S.C. 321(g)(1) (1994).
161For a listing of all seven categorizations, see http://www.fda.gov/cder/handbook/ndabox.htm.
162Id.
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16442 U.S.C. 262(i) (1994).
32an immune response.”165
Biologics, like drugs, are also therapeutic agents, yet historically have been subjected to more rigorous reg-
ulations.166 In addition to regulation by the FDA, biologics were also required to comply with requirements
under the Public Health Services Act (PHSA).
Until passage of the FDAMA, biologics sponsors had to submit a product license application (PLA) and
an establishment license application (ELA) to the CBER. This dual licensing was thought of as unneces-
sary and outdated.167 While the biological products historically were crude and hard to control for quality,
new biological products such as recombinant proteins are produced with the precision and purity of most
traditional pharmaceuticals. The ELA requirements were particularly burdensome because it required the
product used in Phase III studies be produced in a full-scale manufacturing facility.168 This deprived the
company of any manufacturing ﬂexibility, and requires costly upfront investments before the biologic has
been approved for marketing.
Harmonization eﬀorts between the CBER and CDER began in the 1990’s. In an eﬀort to make CBER
and CDER regulation more consistent, the CBER has replaced the two license requirement with a single
application called a Biologics Licensing Application (BLA). 169 A biologics license may be granted if the bi-
ologic is determined to be “safe, pure, and potent” as deﬁned in § 351 of the PHSA.170 A BLA may be ﬁled
with either the CBER or CDER.171 The BLA covers both product quality and manufacturing compliance
of GMP.172 The FDAMA also lessened the burden of the GMP requirements by allowing the product used
165Id.
166Edward L. Korwek, Human Biological Drug Regulation: Past, Present, and Beyond the Year 2000, 50 Food & Drug L.J.
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33in clinical trials to be produced in a small scale or pilot plant.173
Currently, the CBER regulates ﬁve diﬀerent categories of biologics: blood, vaccines, cellular/gene therapy,
tissues, and devices.174 The CBER is responsible for ensuring the integrity of blood and blood components.
The main concern is controlling the spread of infectious diseases such as HIV. The FDA imposes rigorous
donor screening procedures and conducts inspections of blood establishments at least every two years. Also,
the Blood Action Plan was release in 1997, as a measure to ensure better compliance with the Public Health
Service.175 Vaccines are regulated to ensure safety and eﬃcacy, and CBER jointly monitors adverse events
with the Centers for Disease Control & Prevention.176 Regulation of devices includes products used for
the collection of blood, blood components, and cells. CBER also regulates HIV test kits for blood. The
regulation of cell and gene therapy and tissues will be discussed further in Part III.
3.
Regulation of Devices
Section 201(h) of the FDCA deﬁnes the category of “device” broadly as any “instrument, apparatus, im-
plement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any
component, part, or accessory” but it must not “achieve its primary intended purposes through chemical
action within or on the body of man or other animals and which is not dependent upon being metabolized
173Section 124 of FDAMA amending FDCA § 505(c).
174See FDA website for the CBER at http://www.fda.gov/cber/index.html.
175See http://www.fda.gov/cber/blood.htm.
176See http://www.fda.gov/cber/vaccines.htm.
34for the achievement of its primary intended purposes.”177
Devices are divided into three classes of increasing risk and complexity.178 Class I devices pose the least
risk and subject only to general controls.179 Tongue depressors are an example of a Class I device. Class
II devices, such as hearing aids, are subject to special controls.180 Class III pose the most risk and are
thought of as any device that is implanted into the body or used to sustain or support life and has novel
uses, indications, or technology.181 Class III devices must go through a premarket approval process, which
requires clinical trials similar to the drug approval process to demonstrate safety and eﬃcacy.
Class III devices pose the highest risk and therefore must be approved by the FDA before being marketing.
Premarketing approval consists of submitting extensive data summarizing preclinical and clinical tests in
humans. In order to begin clinical studies, the sponsor must ﬁle an Investigational Device Exemption (IDE),
which is the device equivalent of an IND.182 The IND is subject to a 30 day review by the FDA. Premarketing
approval can be obtained either through a traditional premarket approval process (PMA) or through alternate
premarket approval mechanisms called the Modular PMA, Streamlined PMA, or a Product Development
Protocol (PDP).183 All premarket applications require the device to go through preclinical and clinical test
to demonstrate safety184 and eﬃcacy185. The PMA is the more common and traditional approach. The
average review time for PMA’s is 180 days. The FDA approves roughly 40 PMAs per year.186
17721 U.S.C. 321(h) (1994).
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186C. Stephen Lawrence & Randy J. Prebula, Successfully Navigating the Regulatory Environment: Overview of FDA
Regulation-Drugs, Biologics, and Medical Devices, 718 PLI/Pat 935, 955 (2002).
35A modular PMA is similar to a PMA except that instead of submitting all of the required PMA data at one
time, the sponsor can submit to the FDA speciﬁc portions of the PMA as they are ready.187 The sponsor
must ﬁrst meet with the FDA to develop a PMA Shell that outlines the submission plan and schedule.188
The FDA will review each module independently as they are submitted. This reduces the time the FDA
will need to review the application after the clinical trials are complete, and it gives the sponsor the ability
to get feedback earlier on in the trials.
The Streamlined PMA is a pilot program within the Division of Clinical Laboratory Devices.189 This
regulatory pathway is available for devices where FDA guidance exists, FDA has signiﬁcant experience
dealing with similar devices, or the sponsor and FDA jointly develop the protocol. These applications would
receive faster reviews as a result of better coordination with the FDA in the protocol design.
The authority for PDP was created in the 1976 Medical Device Amendments as a faster alternative to the
PMA adding Section 515(f) to the FDCA.190 The PDP functions like a contract between the FDA and
sponsor. The PDP contains all the relevant information about the device, detailed protocols for the clinical
tests, data to be submitted, and performance standards for the tests.191 The FDA must approve the PDP.
Once the sponsor has submitted all the information described in the PDP within the speciﬁed performance
and safety standards, the device is considered approved.192
A “substantially equivalent” exception to a PMA was introduced with the 510(k) notiﬁcation procedure. If
a device was determined to be “substantially equivalent” to a device that has already been approved for
marketing, the manufacturer was allowed to ﬁle a 510(k) Premarket Notiﬁcation (PMN) which is substantially
187See Device Advice, supra note.
188Id.
189See FDA, Letter to IVD Manufacturers on Streamlined PMA (1997) available at http://www.fda.gov/cdrh/pmapilot.pdf.
190David Smith, supra note 170, at 87.
191For detailed description of what a PDP entails see http://www.fda.gov/cdrh/pdp/420.html.
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36less detailed that a PMA and does not require clinical testing.193 “Substantial equivalence” is shown by
demonstrating the device has the same intended use and does not raise any new safety or eﬀectiveness issues
compared to the original device.194
The FDAMA clariﬁed that “substantial equivalence” will be determined from the uses proposed on the
labeling, however, if there is a likelihood that the device is intended for a use not on the label.195 The average
FDA review time for a 510(k) is 110 days.196 The FDAMA also added a new provision allowing qualiﬁed
third parties to review 510(k) notiﬁcations and give a recommendation to the FDA for ﬁnal approval.197
After reviewing the PMA, the FDA may request from clinical data if the device presents any new concerns
or risks.198
The FDAMA introduced two new exceptions to ﬁling a 510(k) PMN. Section 206(a) added a new section
510(l) to the FDCA that exempts most Class I devices from notiﬁcation.199 Section 206(m) includes a list
of Class II devices that the FDA has exempted from a 510(k) notiﬁcation. 200
The Medical Device User Fee and Modernization Act of 2002 (MDUFMA) made three signiﬁcant changes to
the regulation of medical devices.201 First and foremost, it authorized the FDA to collect user fees for certain
medical device applications.202 Through the user fees, the CDRH aims to collect $25,125,000 in 2003 and
increasing to $35,000,000 by 2007.203 The standard fee in 2003 was $154,000.204 Small business applicants
193Rodney R. Munsey, supra note 131, at 168-70.
194Id.
195Section 205(b) of the FDAMA amending 21 U.S.C. 513(i).
196C. Stephen Lawrence & Randy J. Prebula, supra note 186, at 954.
197Section 210 of FDAMA adding 21 U.S.C. § 532.
198Id..
19921 U.S.C. § 510(l).
20021 U.S.C. § 510(m).
201Food and Drug Administration, Summary of the Medical Device User Fee and Modernization Act of 2002 (Nov. 7, 2002).
202Id. at 1.
203Id. at 10. These amounts will be adjusted for inﬂation, workload, and shortfalls in revenue.
204Id. at 5.
37can pay a lower fee of only 38% of the standard fee.205 A small business must have revenues of less than $30
million to qualify.206 Second, it allowed establishment inspections to be conducted by qualiﬁed third parties.
Third, it introduced the “premarket report”, a new type of premarket submission for class III reprocessed
single-use devices that previously required a PMA.207 FDA has committed to certain performance goals in
MDUFMA which will be phased in until 2007.208 The MDUFMA contains a sunset provision providing for
automatic expiration on October 1, 2007.
The MDUFMA also includes a “Bundling Policy” which allows multiple devices to be submitted in one ap-
plication.209 Bundling is especially advantageous with the new user fee policy, as well as streamlining some
of the logistical process. Bundling can also occur for device biologic combinations submitting a BLA.210
Bundling would be appropriate if the review of the devices would be most eﬃcient in a single review.211
Factors that would support a single review include similar data and the similarity of the devices or applica-
tions.212
IV.
205Id.
206Id.
207Id.
208Id. at 7-9.
209Food and Drug Administration, Bundling Multiple Devices or Multiple Indications in a Single Submission, Guidance for
Industry and FDA Staﬀ (Nov. 26, 2003).
210Id. at 3.
211Id. at 4.
212Id. at 5.
38Regulation of New Biotechnologies
In the mid-1980’s the Oﬃce of Science and Technology Policy oﬃcially addressed the question of how
the federal government should regulate biotechnology in a public notice title “Coordinated Framework for
the Regulation of Biotechnology”213. After two years of public comment and discussion among several
agencies, including the FDA, NIH, and the National Science Foundation, the conclusion was that the existing
framework was adequate to regulate the emerging ﬁeld. In the ﬁnal policy statement the FDA announced:
Although there are no statutory provisions or regulations that address biotechnology speciﬁcally,
the laws and regulations under which the agency approves products places the burden of proof of
safety as well as eﬀectiveness of products on the manufacturer. The agency possesses extensive
experience with theses regulatory mechanisms and applies them to the products of biotechnological
processes. In this notice, FDA proposes no new procedures or requirement for regulated industry
or individuals. Rather, the administrative review of products using biotechnology is based on the
intended use of each product on a case-by-case basis.214
The problem was that often these innovative products were not easily categorized into the three existing
categories. This case-by-case approach proved to be confusing and arbitrary.215 Biotechnology soon became
more sophisticated than the simple categories of drug, device, or biologic. The newest technologies often
involved a combination of two or more of these components. Other ﬁelds such as genomics and proteomics
may technically ﬁt into the biologic category, yet introduce complexity that was never imagined when the
category of biologic was ﬁrst conceived.
However, rather than completely changing its infrastructure and approach completely, the FDA approached
the problem by trying to ﬁt these new categories into its existing framework. To help guide industry, the
21349 Fed. Reg. 50,856 (Dec. 31, 1984). The ﬁnal policy statement was released in 1996. 51 Fed. Reg. 23,302 (June 26,
1986).
215For example, some recombinant proteins were classiﬁed as drugs, while others were biologics. See Martha J. Carter, The
Ability of Current Biologics Law to Accommodate Emerging Technologies, 51 Food & Drug L.J. 375, 376 (1996).
39FDA periodically published documents called “Points to Consider” to try and make speciﬁc recommenda-
tions.216 It created a new type of product called combination product, but these products are eventually
regulated primarily by one of the existing three centers and issues outside that center’s expertise are handled
through consultations with other centers.217 Furthermore, the regulatory model is further complicated by
the additional oversight of other government agencies such as the NIH in the case of gene transfer. As
a result, it leaves many in the biotechnology industry confused or overwhelmed by the complexity of the
constantly changing regulatory schemes. Although an Oﬃce of Biotechnology was established in 1990 in the
FDA218 to serve as a liaison between the FDA and the biotechnology community, it was closed in 1994. 219
The following discussion will review the regulatory structure surrounding the three novel areas of biotech-
nology introduced previously. The discussion will also highlight the regulatory and ethical challenges raised
by the technologies, and recommendations for possible improvements.
A.
Cell and Gene Therapy Regulation
The FDA recently announced that many biotech products currently under the regulation of CBER would
move to the CDER. On October 1, 2003, roughly 200 CBER staﬀ was transferred to the CDER.220 The
products that will move to the CDER include “Monoclonal antibodies for in-vivo use; Cytokines, growth
216Id.
217Id.
21855 Fed. Reg. 12,283 (1990).
219Sandra H. Cutter, The Food and Drug Administration’s Regulation of Genetically Engineered Human Drugs, 1 J. Pharmacy
& Law 191, 210 (1992).
220Jill Wechsler, The big shift: FDA explains its plan for moving most biologics under the authority of CDER, Biopharm
International, Mar. 1, 2003, at 16.
40factors, enzymes, immunomodulators, and thrombolytics; Proteins intended for therapeutic use that are
extracted from animals or microorganisms, including recombinant versions of these products (except clotting
factors); Other non-vaccine therapeutic immunotherapies.”221
Within the CBER, a new oﬃce has been established to oversee cel and gene research, the Oﬃce of Cellular,
Tissue and Gene Therapies (OCTGT).222 This and vaccines are the only therapeutics that will remain at
the CBER.223
1.
Cell Therapy
Cell therapy and tissue engineered products were initially regulated as either a biologic or device. However,
neither regulatory structure seemed to be appropriately addressing the new complexities of regulating the
new category of biologics. In 1997 the FDA was directed to reexamine the CBER regulation of human cells,
tissues, and cellular and tissue-based products (HCT/Ps).224 The result of this initiative was summarized
in two documents: “A Proposed Approach to the Regulation of Cellular and Tissue-Based Products”225
and “Reinventing the Regulation of Human Tissues”.226 In these documents, the FDA introduced a new
risk based regulatory scheme that would address the new sophisticated cell therapy and tissue engineering
221Id.
222Id.
223Id.
224President Clinton and Vice President Gore launched a campaign called “Reinventing the Regulation of Human Tissue” in
February of 1997. See Shane M. Ward, supra note 11, at 232.
22562 Fed. Reg. 9721 (Mar. 4, 1997).
226Available at http://www.fda.gov/cber/tissue/rego.htm.
41technologies, while imposing minimal regulation on less sophisticated biologics.227 The Tissue Action Plan
(TAP) was instituted in March 1998 to execute the framework described in those two documents.228 The
goals of the new tissue regulation approach were state as 1) control the spread of infectious disease, 2) prevent
handling or processing that may damage the tissue product, and 3) ensure safety and eﬃcacy of products
that posed a higher risk.229
The new framework allows “minimally manipulated” 230 HCT/Ps to be regulated solely by § 361 of the
PHSA to control communicable diseases.231 Minimal manipulation includes procedures such as cell selection
or separation, sterilization, cryopreservation, freezing, cutting, and grinding.232
An HCT/P must go through the full premarket approval process of a drug, device, or biologic if any one of
the following conditions apply:
•
The HCT/P is more than minimally manipulated;
•
The HCT/P is intended for a nonhomologous233 use, meaning the HCT/P
is being used for a function diﬀerent from its original function;
227See Shane M. Ward, supra note 11, at 234.
228The core team for TAP meets monthly and has eleven working groups. See http://www.fda.gov/cber/tissue/tapfyrpts.htm.
229Martha A. Wells, Overview of FDA Regulation of Human Cellular and Tissue-Based Products, 52 Food & Drug L.J. 401,
406 (1997).
230“Minimal Manipulation” is statutorily deﬁned as “(1) For structural tissue, processing that does not alter the original
relevant characteristics of the tissue relating to the tissue’s utility for reconstruction, repair, or replacement; and (2) For cells
or nonstructural tissues, processing that does not alter the relevant biological characteristics of cells or tissues.” 21 C.F.R. §
1271.3.
23121 CFR § 1271.10.
232FDA, Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment Registration and Listing, 66 Fed.
Reg. 5447, 5457 (2001).
42•
The manufacture of the HCT/P involves the combination of the cell
or tissue component with a drug or a device (does not include minimal contact with
nonbiologic for sterilizing, preserving, or storing purposing) or
• The HCT/P has a systemic eﬀect or is dependent upon the metabolic activity of living cells for its
primary function.
HCT/Ps explicitly excused from premarket approval include HCT/Ps that have a system eﬀect or depend
on metabolic activity, but is for autologous use, is for allogeneic use in a ﬁrst or second-degree blood relative,
or is for reproductive use.
All HCT/Ps are subject to comply with Good Tissue Practices (GTPs). These GTP’s are contained in the
following documents:
•
Final Rule – Human Cellular And Tissue-Based Products; Establishment
Registration and Listing234;
•
Proposed Rule – Suitability Determination For Donors of Human Cellular
And Tissue-Based Products235; and
• Proposed Rule –Current Good Tissue Practice for Manufacturers of Human Cellular and Tissue-Based
Products; Inspection and Enforcement.236
The Final Rule requires that all HCT/P establishments register with the FDA and all HCT/P products
must also be listed with the FDA. Some HCT/Ps are excused from the registration and listing requirement
23666 Fed. Reg. 1508 (Jan. 8, 2000).
43include tissues transplanted in the same individual during the same surgical procedure and establishments
that collect only reproductive cells and transfer them immediately to the donor’s partner, e.g. in vitro fer-
tilization clinics.237
Some HCT/P’s fall outside the FDA regulatory framework but are subject to other regulations in addition
the PHSA. Bone marrow and whole organ transplantation that do not involve more than minimal manipu-
lation of the tissue is regulated by the Health Resource Services Administration (HRSA).238 Within HRSA,
the National Marrow Donor Program has speciﬁc standards for bone marrow.
Also, the CBER has recently issued detailed guidance on cell therapy using xenotransplantation239. The
guidelines build upon the PHS Guideline on Infectious Disease Issues in Xenotransplantation issued in
2001240. In the guidance, the FDA deﬁnes xenotransplantation broadly any procedure using nonhuman cell,
tissues, or organs and also any procedure that involves human cell, tissues, or organs coming into ex vivo
contact with an animal product.241
Some conﬂict has occurred over biologic/device combination products. The Tissue Reference Group within
TAP was formed in 1998 to resolve jurisdictional conﬂicts for tissue engineering and cell therapy products.242
The CBER also started a Device Action Plan in 1999 and established a Device Management Team to oversee
regulation of devices within CBER.243
23721 C.F.R. § 1271.15.
238SR Burger, Current Regulatory Issues in Cell and Tissue Therapy, 5 Cytotherapy 289, 290 (2003).
239FDA CBER, Guidance for Industry: Source Animal, Product, Preclinical,and Clinical Issues Concerning the Use of Xeno-
transplantation Products in Humans (April 2003).
240Available at http://www.fda.gov/cber/gdlns/xenophs0101.htm.
241Id.
242John Miller, supra note 114, at 9.
243Id.
442.
Gene Therapy
Gene therapy is unique in its regulation because both the FDA and the NIH have signiﬁcant oversight over
the clinical trials. The NIH established its involvement with the regulation of rDNA research. In 1974
researchers at Stanford University proposed to transplant DNA from a cancer causing virus into the E.coli
bacteria that is found commonly in the human intestine244. This caused alarm in the scientiﬁc community
and the researchers were asked to postpone the research until the risks around the research could be explored.
The NIH took primary responsibility for determining the future of rDNA research.
The NIH is an agency whose principal purpose is to support and fund medical research for the nation245.
The NIH does not have regulatory power per se, but rather holds power by controlling the use of government
research funding. Therefore, although NIH guidelines apply only to institutions receiving NIH funding,
almost all current research is conducted with some aﬃliation to government funding or an institution receiving
government funding246. Even if the research is completely privately funded, most researchers will voluntarily
comply with NIH Guidelines.
Recognizing the importance of the new technology, the NIH established the Recombinant DNA Advisory
Committee (RAC).247 A few years later the RAC developed strict guidelines govern rDNA research248. The
guidelines established that all protocols involving rDNA must be registered with the NIH.249 In 1984 the
RAC established a working group to begin developing guidelines for gene transfer studies that would be done
244Id.
245See The NIH Almanac, available at http://www.nih.gov/about/almanac/index.html (describing the mission statement of
the NIH).
246NIH Guidelines for Research Involving Recombinant DNA Molecules (May 1998) § I.C.1.a.
247Joseph M. Rainsbury, supra note 60, at 576.
248Judith A. Cregan, supra note 66, at 273.
249Id.
45in humans250. The working group completed the guidelines for human studies in 1985, in a document called
Points to Consider251.
The ﬁrst human gene transfer trial came ﬁve years later in 1990 and was reviewed 14 times before it was
approved.252 At that point the Points to Consider for gene transfer was oﬃcially added the NIH Guidelines
as Appendix M.253 Since then the regulation imposed on gene research has been amended several times
and involves a complicated network of players, including the FDA, NIH, IRB, IBC, and local oversight
mechanisms.
In 1991 the FDA issued its own guidance called “Points to Consider in Human Somatic Cell Therapy and
Gene Therapy”254. To aﬃrm its regulatory role even further, the FDA release a statement in the 1993
Federal Register stating that the FDA’s authority provided in the FDCA and PHSA was broad enough
to cover cell and gene therapy.255 In the years following, RAC’s authority over gene therapy continued to
decline. In 1995, RAC approval was limited to only those protocols that were determined to be novel. 256
The process was referred to as “consolidated review” in an eﬀort to eliminate what was thought of as double
review by both the NIH and FDA.257
RAC’s regulatory authority over gene transfer protocols was relinquished to the FDA completely in October
1997, and RAC approval was no longer needed for any gene transfer protocols258. The only exception is if
three members of the RAC decide that a particular protocol is so novel and controversial that it warrants
public debate259. The CBER at the FDA took over as primary regulatory authority over protocol approvals
250Nancy M. P. King, supra note 72, at 381.
251Id.
252Edward L. Korwek, supra note 166, at n.203.
253Nancy M. P. King, supra note 72, at 381.
254Joseph M. Rainsbury, supra note 60, at 581.
255Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products, 58
Fed. Reg. at 53,248 (Oct. 14, 1993).
256See 60 Fed. Reg. 20,726 (1995).
257Edward L. Korwek, supra note 166, at146.
25862 Fed. Reg. 59,032 (1997).
25962 Fed. Reg. at 4783.
46through the IND process. However, research that receives NIH funding or is associated with an institute
receiving NIH funding must still comply with the NIH Guidelines, register the protocol with the OBA, and
receive IRB and Institutional Biosafety Committee (IBC) approval. The IRB and IBC serve as the local
oversight bodies. The IRB focuses on patient safety and the IBC is charged with other scientiﬁc aspects
such as laboratory and environmental safety. With the loss of approval power over clinical protocols, some
have wondered whether the RAC has lost some respect within the biomedical community.260 Although the
RAC has long been well respected, the future role of the RAC remains unclear. The RAC is a long standing
and respected institution, and should be. The RAC should still serve as the liaison to public debate and is
the proper forum for looking at the ethical and social issues gene therapy raises.
The question remains whether the current system can adequately protect the public health without unduly
hindering the progress of breakthrough research. Currently the FDA does not conduct inspections of clinical
trials in gene therapy. It has added a new provision requiring the investigator to hire an independent third
party to conduct random inspections261. A Gene Transfer Safety Symposium has been recommended by
Senator Edward Kennedy262.
Informed consent is another issue that was brought to the forefront in the Jesse Gelsinger death. Both the
FDA and NIH have requirements for informed consent. However, do to some information deﬁciencies, neither
the FDA or NIH can be sure that informed consent forms contain all the relevant information that a patient
would need to make the most informed decisions.263
The FDA and NIH recently jointly launched a new database Genetic Modiﬁcation Clinical Research Infor-
260Joseph M. Rainsbury, supra note 60, at 592.
261FDA to Crack Down on Monitoring Patients Undergoing Gene Therapy, TRANSPLANT NEWS, Mar. 13, 2000, available
in LEXIS, News Library.
262Aaron Zitner, Kennedy’s Bill Would Create Gene Therapy Oversight Panel: Clinton Administration Also Seeks New Rules
for Tests, BOSTON GLOBE, Mar. 7, 2000, at E5.
263See Judith A. Cregan, supra note 66, at 281.
47mation System (GeMCRIS) - a Web-accessible database of human gene transfer trials that the two agencies
developed collaboratively.264
Some reports have emerged of interagency rivalry that may be harming the regulatory framework265. One
commentator at a Senate hearing stated, “on several critical matters, there’s been a lack of appropriate
cooperation between the FDA and the NIH.266
For example while both the FDA and NIH require adverse event reporting, inconsistent reporting require-
ments for adverse events for the NIH and FDA has caused confusion with researchers267. First, FDA requires
life threatening or unexpected adverse events to be reported as soon as possible, but no later than seven
days after the event. All other serious adverse events must be reported within 15 days. The NIH simply re-
quired immediate reporting of all adverse events, yet provides to deﬁnition for a serious adverse event. Data
conﬁdentiality was also inconsistent between the FDA and NIH. While the FDA is statutorily bound to keep
all information submitted in the IND conﬁdential, the NIH’s position is to make any and all information
available to the public. Furthermore, after the death of Jesse Gelsinger, investigation into all the current
clinical trials using a similar adenovirus vector revealed that out of 691 adverse events that had occurred,
39 were promptly reported to the NIH.268
The NIH recently made a signiﬁcant eﬀort to harmonize its regulation with the FDA.269 This statement
was released in 2001 and harmonized the adverse event reporting timelines and assured the industry that
264See http://www.gemcris.od.nih.gov/
265Judith A. Cregan, supra note 66, at 282; Gregory A. Jaﬀe, Inadequacies in the Federal Regulation of Biotechnology, 11
HARV. ENVTL. L. REV. 491, note 12 (1987).
266Judith A. Cregan, supra note 66, at 282 (2000) (quoting Dr. Walters from Gene Therapy: Is There Oversight for Patient
Safety: Hearings Before the Subcomm. On Public Health of the Senate Comm. On Health, Education, Labor and Pensions,
106th Cong. 76 (2000)).
267NIH Gene Therapy AE Reporting Standards Less Clear Than FDA, BLUE SHEET, Mar. 22, 2000, available in 2000 WL
8519047.
268Wilder J. Leavitt, Regulating Human Gene Therapy: Legislative Overreaction to Human Subject Protection Failures, 53
Admin. L. Rev. 315, 330 (2001).
269NIH, Recombinant DNA Research: Actions Under the
NIH Guidelines, 66 Fed. Reg. 57970, Nov. 19, 2001.
48proprietary or trade secret information in the adverse event report would be kept conﬁdential.270
B.
Pharmacogenomics Regulation
The regulation of pharmacogenomics industry is bifurcated into two pathways with drugs and its related
genetic tests being regulated by the FDA271 and stand alone predictive genetic tests conducted in laborato-
ries falling under the responsibility of the Centers for Disease Control and the Human Health Services272.
Pharmacogenomics and genetic testing raises several social and ethical issues such as conﬁdentiality and
exacerbating the orphan drug problem273.
1.
Pharmacogenomic Drugs
Drugs that are made targeted to a speciﬁc gene, the manufacturer must present all relevant genomic data to
the FDA in the PMA. However, when the genetic information is used as only one factor in the drug’s safety
or dosing, the FDA’s pharmacogenomic data submission requirements have been less clear. Manufacturers
270Id.
271See 62 Fed. Reg. 62,243, 62,259-60 (Nov. 21, 1997)
272See Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. § 263a (2000); 65 Fed. Reg. 25,928 (May 4, 2000).
273See, e.g., Legal Liabilities at the Frontier of Genetic Testing, 41 JURIMETRICS J. 1 (2000); Michael J. Malinowski &
Robin J.R. Blatt, Commercialization of Genetic Testing Services: The FDA, Market Forces, and Biological Tarot Cards, 71
TUL. L. REV. 1211 (1997).
49of drugs have been reluctant to submit to pharmacogenomic data to the FDA because of the uncertainty
around how the data should be submitted and fears over what aﬀect the data would have on the drug’s
approval.274 The FDA made an eﬀort to clarify their policy and encourage data submissions with a recently
published a guidance document for industry.275
The FDA clariﬁed that it will not be mandating genetic tests with the development new drugs.276 However,
if the sponsor conducts genetic tests in connection with drug development, then under certain circumstances,
the sponsor will be required to include that data with the IND, NDA, or BLA.
The FDA outlines guidelines for when pharmacogenomic data will be required and when submission is
only voluntary. If a pharmacogenomic test was a deciding factor in aspects of the study relating to safety,
eﬀectiveness, or dosing, then the sponsor must submit the data to the FDA.277 If the drug labeling includes
genetic information on the labeling, then the application must include the complete genetic data that supports
such labeling. Furthermore, the sponsor is also required to submit the data if the test is considered a valid
biomarker.278 If the test is a valid biomarker, but not related to the drug’s safety, eﬀectiveness, or dosing,
data submission is still required, but may be submitted in an abbreviated report. The FDA considers
a pharmacogenomic test to be a valid biomarker if “(1) it is measured in an analytical test system with
well established performance characteristics and (2) there is an established scientiﬁc framework or body
of evidence that elucidates the physiologic, pharmacologic, toxicologic, or clinical signiﬁcance of the test
results.”279 For example, a well established genetic test for variances in the gene that encodes the drug
274Id.
275Food and Drug Administration, Guidance for Industry: Pharmacogenomic Data Submissions, 23 Biotechnology L. Rep. 68
(2004).
276Id.
277Food and Drug Administration, Guidance for Industry: Pharmacogenomic Data Submissions, 23 Biotechnology L. Rep.
68, 74 (2004).
278Id.
279See generally Food and Drug Administration, Guidance for Industry: Pharmacogenomic Data Submissions, 23 Biotechnol-
ogy L. Rep. 68 (2004).
50metabolizing enzyme cytochrome P450 would be considered a valid biomarker.280
If the pharmacogenomic tests were purely exploratory, e.g. looking at general gene expression, or if the test
are not considered a valid biomarker, then submission of the data is purely voluntary.281 These Voluntary
Genomic Data Submissions (VGDS) are highly encouraged by the FDA because they would allow the FDA
to stay educated on the latest advances in genetic tests.282 In order to minimize the burden of submitting
the voluntary information, the FDA has no stringent format requirements for data submissions.283 With
some guidelines for content, a sponsor could even submit an article that was submitted to scientiﬁc journal
as their data submission.284 FDA further clariﬁed that any voluntary submission of data would not aﬀect
the decision making process for the approval of the drug.285
Required pharmacogenomic data will aﬀect regulatory decisions as one of the many factors of drug safety
and eﬃcacy.286 As a result, the FDA may recommend as part of approval that the sponsor add the genetic
risk factors to the drug labeling. Also, if the sponsor tested the drug in a population with a speciﬁc geno-
type, then the FDA would require that the corresponding pharmacogenomic diagnostic test be developed in
conjunction with the drug as a condition of approval.
280Id.
281Id.
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512.
Genetic Tests
Genetic testing has raised concerns over discrimination that could result from the information, especially by
employers or insurance companies. In 2000, President Clinton issued an executive order prohibiting the use
of genetic information in the hiring, promoting, discharging, and all employment decisions287. The Equal
Employment Opportunity Commission takes a similar stance against using genetic information for employ-
ment decisions288. Besides risks with the use of information, genetic tests may result in some dangerous
results. First, is the phychological damage that could occur if a person is falsely diagnosed to have a fatal
disease.
Predictive gene testing that is given as a service and not linked to a product is not subject to the safety and
eﬃcacy requirements of the FDA. Rather regulation falls under the Clinical Laboratory Improvements Act
and Amendments (CLIA)289. CLIA oversight of laboratories is sporadic and unsuﬃcient, with more than
150,000 CLIA certiﬁed laboratories that need oversight and frequent reporting deﬁciencies and infrequent
laboratory inspections290. In a recent survey of 245 laboratories oﬀering genetic testing, 15 percent of the
labs received a quality score of less than 70 percent.291 The quality and reliability of some genetic tests
have been questioned, with one woman in 1999 who almost mistakenly had her ovaries removed based on an
erroneous genetic test for a cancer gene.292
287Executive Order to Prohibit Discrimination in Federal Employment Based on Genetic Information, Exec. Order No. 13,145
(Feb. 8, 2000), 65 Fed. Reg. 6,877.
288EEOC Compliance Manual § 902.8 (1995).
289Pub. L. No. 100-578, 102 Stat. 2903 (1994).
290Snake Oil, supra note 91.
291Judy Peres, Genetic Testing Can Save Lives – But Errors Leave Scars, Chi. Trib. Sept. 26, 1999, at 1.
292See Genetic Testing’s Human Toll: In Unregulated Field, Erros can Upend Lives and Mean Unneeded Surgery, Wash. Post,
July 21, 1999, at A01.
52Due to the lack of regulation of some genetic tests, both the public and industry has suﬀered. The public may
become victim to misleading or false genetic tests that could lead them to receive unnecessary or dangerous
treatments. Manufacturers genetic tests in general suﬀer from lack of regulation as well as the public loses
conﬁdence and trust in this emerging ﬁeld of technology because there is no reliable way to distinguish
between valid tests and those with no merit.293
Given the lack of CLIA to ensure product quality, the FDA is the best positioned, both from an infrastructure
and experience standpoint, to take responsibility for oversight of stand alone predictive genetic testing.
The FDA is already familiar with the technology as it already reviews diagnostic genetic test kits used
in combination with drugs. The Advisory Committee at the Centers for Disease Control has published
recommendations for quality assurance programs for laboratory genetic testing that the FDA could use as a
resource for crafting their regulations294.
C.
Novel Drug Delivery Regulation
Almost all novel drug delivery devices will be a combination product, and thus must interact with more
than one FDA center to gain approval. The combination products approach has had its limitations. It has
been noted that “manufacturers dread combination products because of the inherent diﬃculties of dealing
with more than one FDA Center.” The FDA took a step forward by developing the Oﬃce of Combination
293See Snake Oil, supra note 91(discussing how the lack of regulation has “demonized” the technology in both the medial
community and general public).
294Eugene C. Cole, Centers for Disease Control & Prevention, Contract No. 200-98-0011, General Recommen-
dations for Quality Assurance Programs for Laboratory Molecular Genetic Tests (Aug. 31, 1999), available at
http://www.phppo.cdc.gov/DLS/pdf/genetics/dyncor.pdf.
53Products to address some of the complaints, however problems still plague the system.
Combination products were ﬁrst oﬃcially recognized in a statute in 1990 in the Safe Medical Devices Act of
1990. The act added § 503(g) to the FDCA prescribed how regulation of combination should be handled by
the FDA. One of the FDA’s centers - CDER, CBER, or CDRH - would be assigned as a primary reviewer
based on the combination drug’s “primary mode of action”.295 Past regulation of combination products has
been criticized for being lengthy and inconsistent.296
The “primary mode of action” is a diﬃcult test to apply to many biotechnology products where the mech-
anism of action is not always known. Looking at the past jurisdiction of some combination products, the
determination of which center takes lead is not always intuitive. The “cultured skin” products were regulated
by the CDRH, although the FDA questioned whether jurisdiction should be transferred to the CBER.297
The to alleviate some of the jurisdictional conﬂict, three intercenter agreements were drafted between each
of the FDA centers.298 However, the intercenter agreements were not clear as to the basis of assignment for
a particular product.299 Also, in some cases it has taken up to 13 months just to determine which center
has primary jurisdiction.300
The MDUFMA introduced a new Oﬃce of Combination Products under the Commissioner’s Oﬃce to try
and address some of these issues of eﬃciency and timeliness.301 The oﬃce was established on December 24,
2002.302 The OCP has been tasked with addressing several of the problems described. An internal working
29521 U.S.C. 353(g)(1).
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54group has been charged with the task of deﬁning “primary mode of action”. The Oﬃce also committed to
making decisions on an RFD within 60 days of receipt. The centers have created nine combination product
categories:
(1) convenience kit of package
(2) preﬁlled drug delivery device/system
(3) preﬁlled biologic delivery device/system
(4) device coated/impregnated/otherwise combined with drug
(5) device coated or otherwise combined with biologic
(6) drug/biologic combination
(7) separate products requiring mutually conforming labeling
(8) possible combination based on mutally conforming labeling of separate products
(9) other type of combination product
A recent report summarizing FDA employee perspectives on the regulation of combination products revealed
several shortcomings of the current system.303 One area of improvement that was identiﬁed was for earlier
identiﬁcation of a combination product issue. Sometimes, other centers were not brought into consultation
until after the clinical trials were completed.304 The earlier the relevant centers are involved, the better
guidance the sponsor can receive. Even when a sponsor chooses to submit an oﬃcial Request for Designation
(RFD), complaints of arbitrariness and lack of communication have been reported.305 Some of the limitations
of the Combination Products Program is also cultural. Some employees reported a reluctance to engage
another center, even when their input would be appropriate.306
Although the objective for all three centers is the ensure the safety and eﬃcacy of approved products, each
center has its own distinct and separate process and procedures this is requires an applicant to follow.
303See Combination Products Program, Regulation of Combination Products: FDA Employee Perspectives (October 2002).
304See Id.
305See Id.
306See Id.
55These diﬀerences are signiﬁcant in that it means diﬀerence data or testing requirements. For example, a
combination drug-device would be subject to both the Quality Systems Regulation for the device component
and Good Manufacturing Practices for the drug component.307
Some manufacturers have complained of inconsistency in the application requirements or some device manu-
facturers might not have the capabilities or systems in place to meet the GMP standards. Similar complaints
with the adverse reporting system have also been reported. A combination product manufacturer would have
to report the same adverse event to multiple centers in diﬀerent formats which is ineﬃcient and duplicative.
While the CBER and CDER have been working to harmonize their regulations, similar progress has not been
make to incorporate the CDRH, and some representatives at CDRH reported that after an adverse event
“considerable ‘fumbling around’ sometimes occurs in determining jurisdiction and/or engaging a consultant
from CBER or CDER when a combination product issue emerges.”308.
Another problem with the combination products program is the lack of information management systems
to support consultations. Although each center has electronic data tracking systems, the systems are not
on the same platform and not integrated with each other to share information.309 Furthermore, none of
tracking systems identify whether a product is a combination or the status of a consultation.310
307Id.
308Combination Products Program, Regulation of Combination Products: FDA Employee Perspectives, 12 (October 2002).
309Id.
310Id. at 13.
56V.
Conclusion
Now that the FDA has realized that new biotechnology does not easily ﬁt into its traditional regulatory
framework, it should continue to work to match the pace of the rapidly changing industry. At one time it
may have made sense to simply try and ﬁt some of the new biotechnology into existing categories, but as
complex combination products become the standard medical products instead of the exception, it may no
longer be eﬃcient to hold steadfastly to the old structure.
One overall improvement to biotechnology regulation would be to make the Oﬃce of Combination Products
a new Biotechnology Center, with the reviewing agents located in one center, instead of merely acting as a
jurisdictional liaison. This would avoid the need for cumbersome intercenter agreements and potential for
miscommunication and turf wars. Having a center dedicated to biotechnology would also address some of
the problems of agency workload and expertise.
Already, the agency staﬀ within the three centers are being diverted to contribute to consultations. Con-
solidating the reviews into one center would be a more eﬃcient use of reviewers time. Furthermore, the
biotechnology center could be divided into functional practice groups, such gene transfer, pharmacogenomics,
and drug delivery. This would allow staﬀ the ability to focus and build expertise in one area, while giving
industry a clearer idea of who would be responsible for the reviews.
While this type of reorganization would be a dramatic departure from the current structure, it is clear that
biotechnology is not just a passing trend, but it is here to stay, and may hold the future for where medicine
is heading.
Also, just as the 501(k)’s have been outsourced to qualiﬁed third parties, the FDA should continue to look
57for non-core areas and functions that would allow the FDA to concentrate on activities that make the best
use of its time and resources.
Several industry surveys have stated that the industry feels that the FDA lacks the technical expertise and
that is contributing to regulatory delays.311 The FDA should continue its trend of looking to outside sources
of advice and support. The FDA must keep training and retention of its staﬀ as a top priority. As the
FDA staﬀ is pressured to continue to speed review times, they may have less opportunity for training and
development. FDA collaborations with other agencies such as the NIH, National Science Foundation, and
National Cancer Institute will be essential for the FDA to stay abreast on the most current scientiﬁc issues.
While the new frontier of biotechnology raises several challenging regulatory issues, it also brings an opportu-
nity to build a new regulatory structure that is more responsive and ﬂexible to rapid advances in technology.
Already, the science is advancing at remarkable speeds. Genes and DNA are no longer the smallest building
blocks that medical science is targeting. The new area of nanotechnology is now looking for solutions at
the molecular level312. The next advances in biotechnology are sure to bring about unforeseen complexities
spanning scientiﬁc, regulatory, social, and ethical issues. The FDA can best serve as the guardian of public
health by being prepared for the unexpected and remaining open to the possibility of change within its own
organization.
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